JH-RE-06

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

JH-RE-06  纯度: 99.87%

JH-RE-06, 有效的 REV1-REV7 互作抑制剂 (IC50=0.78 μM; Kd=0.42 μM)，靶向与 POLζ 的 REV7 亚基相互作用的 REV1。JH-RE-06 通过阻止诱变 POLζ 的募集来破坏诱变性跨损伤合成 (TLS)。JH-RE-06 可改善化疗效果。

JH-RE-06

JH-RE-06 Chemical Structure

CAS No. : 1361227-90-8

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥7321 In-stock
1 mg ￥3900 In-stock
5 mg ￥7100 In-stock
10 mg ￥12000 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

JH-RE-06 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus

生物活性

JH-RE-06, a potent REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ. JH-RE-06 improves chemotherapy[1][2].

IC50 & Target

IC50: 0.78 μM (REV1-REV7)[1]
Kd: 0.42 μM (REV1-REV7)[1]
体外研究
(In Vitro)

JH-RE-06 unexpectedly induces dimerization of the REV1 CTD at its REV7-binding surface and blocks the REV1-REV7 interaction[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

JH-RE-06 inhibits mutagenic TLS and enhances cisplatin-induced toxicity in cultured human and mouse cell lines[1].
Co-administration of JH-RE-06 with cisplatin suppresses the growth of xenograft human melanomas in mice[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

468.72

Formula

C20H16Cl3N3O4
CAS 号

1361227-90-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 5 mg/mL (10.67 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.1335 mL 10.6673 mL 21.3347 mL
5 mM 0.4267 mL 2.1335 mL 4.2669 mL
10 mM 0.2133 mL 1.0667 mL 2.1335 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Wojtaszek JL, et al. A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy. Cell. 2019 Jun 27;178(1):152-159.e11.

    [2]. REV1-POLς Inhibition Enhances Cisplatin-Induced Cytotoxicity. Cancer Discov. 2019 Aug;9(8):OF17.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务